...
search icon
clls-img

Cellectis SA, Common Stock

CLLS

NMQ

$1.61

+$0.03

(1.9%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$161.15M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
65.04K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
3.20
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.41 L
$3.38 H
$1.61

About Cellectis SA, Common Stock

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCLLSSectorS&P500
1-Week Return-3.59%1.77%-0.48%
1-Month Return-10.56%6.76%3.25%
3-Month Return-9.55%-6.43%
6-Month Return-28.12%-1.84%9.96%
1-Year Return-46.15%4.62%25.34%
3-Year Return-74.07%11.92%34.47%
5-Year Return-89.59%48.14%88.14%
10-Year Return-95.9%110.84%200.56%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue15.19M73.95M73.95M19.17M755.00K[{"date":"2019-12-31","value":20.54,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":25.92,"profit":true},{"date":"2023-12-31","value":1.02,"profit":true}]
Cost of Revenue11.39M36.27M36.27M1.77M737.00K[{"date":"2019-12-31","value":31.4,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":4.88,"profit":true},{"date":"2023-12-31","value":2.03,"profit":true}]
Gross Profit3.80M37.67M37.67M17.40M18.00K[{"date":"2019-12-31","value":10.08,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":46.18,"profit":true},{"date":"2023-12-31","value":0.05,"profit":true}]
Gross Margin25.00%50.95%50.95%90.76%2.38%[{"date":"2019-12-31","value":27.55,"profit":true},{"date":"2020-12-31","value":56.13,"profit":true},{"date":"2021-12-31","value":56.13,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":2.63,"profit":true}]
Operating Expenses127.35M123.11M123.11M107.06M97.32M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":96.67,"profit":true},{"date":"2021-12-31","value":96.67,"profit":true},{"date":"2022-12-31","value":84.07,"profit":true},{"date":"2023-12-31","value":76.42,"profit":true}]
Operating Income(123.55M)(85.44M)(85.44M)(89.67M)(106.63M)[{"date":"2019-12-31","value":-12355200000,"profit":false},{"date":"2020-12-31","value":-8543700000,"profit":false},{"date":"2021-12-31","value":-8543700000,"profit":false},{"date":"2022-12-31","value":-8966600000,"profit":false},{"date":"2023-12-31","value":-10662600000,"profit":false}]
Total Non-Operating Income/Expense12.87M(13.36M)(16.21M)(17.87M)(19.23M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-103.82,"profit":false},{"date":"2021-12-31","value":-125.93,"profit":false},{"date":"2022-12-31","value":-138.85,"profit":false},{"date":"2023-12-31","value":-149.43,"profit":false}]
Pre-Tax Income(115.21M)(97.48M)(97.48M)(98.60M)(123.05M)[{"date":"2019-12-31","value":-11521200000,"profit":false},{"date":"2020-12-31","value":-9748300000,"profit":false},{"date":"2021-12-31","value":-9748300000,"profit":false},{"date":"2022-12-31","value":-9860100000,"profit":false},{"date":"2023-12-31","value":-12304600000,"profit":false}]
Income Taxes(24.53M)(24.91M)(11.20M)87.00K(6.21M)[{"date":"2019-12-31","value":-28190.8,"profit":false},{"date":"2020-12-31","value":-28634.48,"profit":false},{"date":"2021-12-31","value":-12877.01,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-7139.08,"profit":false}]
Income After Taxes(90.69M)(72.57M)(86.28M)(98.69M)(116.83M)[{"date":"2019-12-31","value":-9068600000,"profit":false},{"date":"2020-12-31","value":-7257100000,"profit":false},{"date":"2021-12-31","value":-8628000000,"profit":false},{"date":"2022-12-31","value":-9868800000,"profit":false},{"date":"2023-12-31","value":-11683500000,"profit":false}]
Income From Continuous Operations(115.21M)(97.48M)(125.11M)(98.69M)(116.83M)[{"date":"2019-12-31","value":-11521200000,"profit":false},{"date":"2020-12-31","value":-9748300000,"profit":false},{"date":"2021-12-31","value":-12510700000,"profit":false},{"date":"2022-12-31","value":-9868800000,"profit":false},{"date":"2023-12-31","value":-11683500000,"profit":false}]
Income From Discontinued Operations(43.90M)(43.90M)(28.36M)(15.35M)-[{"date":"2019-12-31","value":-4390200000,"profit":false},{"date":"2020-12-31","value":-4390200000,"profit":false},{"date":"2021-12-31","value":-2835800000,"profit":false},{"date":"2022-12-31","value":-1534500000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(90.69M)(72.57M)(86.28M)(98.69M)(101.06M)[{"date":"2019-12-31","value":-9068600000,"profit":false},{"date":"2020-12-31","value":-7257100000,"profit":false},{"date":"2021-12-31","value":-8628000000,"profit":false},{"date":"2022-12-31","value":-9868800000,"profit":false},{"date":"2023-12-31","value":-10105900000,"profit":false}]
EPS (Diluted)(2.41)(1.93)(2.53)(2.34)(1.78)[{"date":"2019-12-31","value":-241,"profit":false},{"date":"2020-12-31","value":-193,"profit":false},{"date":"2021-12-31","value":-253,"profit":false},{"date":"2022-12-31","value":-234,"profit":false},{"date":"2023-12-31","value":-178,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CLLS
Cash Ratio 1.58
Current Ratio 1.78
Quick Ratio 1.75

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CLLS
ROA (LTM) -16.09%
ROE (LTM) -82.20%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CLLS
Debt Ratio Lower is generally better. Negative is bad. 0.67
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.33

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CLLS
Trailing PE NM
Forward PE NM
P/S (TTM) 4.47
P/B 1.25
Price/FCF NM
EV/R 3.74
EV/Ebitda NM
PEG NM

FAQs

What is Cellectis SA share price today?

Cellectis SA (CLLS) share price today is $1.61

Can Indians buy Cellectis SA shares?

Yes, Indians can buy shares of Cellectis SA (CLLS) on Vested. To buy Cellectis SA from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CLLS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Cellectis SA be purchased?

Yes, you can purchase fractional shares of Cellectis SA (CLLS) via the Vested app. You can start investing in Cellectis SA (CLLS) with a minimum investment of $1.

How to invest in Cellectis SA shares from India?

You can invest in shares of Cellectis SA (CLLS) via Vested in three simple steps:

  • Click on Sign Up or Invest in CLLS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Cellectis SA shares
What is Cellectis SA 52-week high and low stock price?

The 52-week high price of Cellectis SA (CLLS) is $3.38. The 52-week low price of Cellectis SA (CLLS) is $1.41.

What is Cellectis SA price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Cellectis SA (CLLS) is 1.25

What is the Market Cap of Cellectis SA?

The market capitalization of Cellectis SA (CLLS) is $161.15M

What is Cellectis SA’s stock symbol?

The stock symbol (or ticker) of Cellectis SA is CLLS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top